Key result
Metabolic syndrome linked to ~200% higher CHD risk, requiring weight loss and exercise to prevent CVD.
This review highlights that metabolic syndrome triples coronary heart disease risk and discusses its pathogenesis and management in women, including its relationship with polycystic ovarian syndrome.
May aid CHD risk stratification in practice; leaves open whether syndrome-specific therapies improve outcomes beyond lifestyle.
The risk of developing cardiovascular disease has recently been associated with a set of metabolic and physiological risk factors that include abdominal obesity, atherogenic dyslipidemia, hypertension, and elevated plasma glucose. The term most commonly used to describe this conglomeration of risk factors is the metabolic syndrome. Coronary heart disease risk is tripled in those individuals with this syndrome. Primary treatment focuses on weight reduction and physical activity to reduce risk factors and prevent the progression to cardiovascular disease. This article will review the definition, prevalence, pathogenesis, and treatment of the metabolic syndrome in women and will discuss the role of polycystic ovarian syndrome in relation to the metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2005) conducted a review in Metabolic syndrome. Metabolic syndrome was evaluated. The metabolic syndrome triples the risk of coronary heart disease and requires primary treatment focusing on weight reduction and physical activity to prevent progression to cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: